Limits...
A randomised controlled trial evaluating the impact of targeted vitamin D supplementation on endothelial function in type 2 diabetes mellitus: The DIMENSION trial.

Dalan R, Liew H, Assam PN, Chan ES, Siddiqui FJ, Tan AW, Chew DE, Boehm BO, Leow MK - Diab Vasc Dis Res (2016)

Bottom Line: We compared the change from baseline parameters in the two groups using Student's t-test or Kruskal-Wallis test.The median reactive hyperaemia index in the vitamin D group increased from 0.65 (interquartile range: 0.42) to 0.73 (interquartile range: 0.36), whereas it decreased from 0.73 (interquartile range: 0.65) to 0.65 (interquartile range: 0.38) (p = 0.02) in the placebo group.After adjustment for baseline variables, the change was not statistically significant for reactive hyperaemia index (p = 0.07) and for other vascular biomarkers (p > 0.05).

View Article: PubMed Central - PubMed

Affiliation: Department of Endocrinology, Tan Tock Seng Hospital, Singapore Yong Loo Lin School of Medicine, National University of Singapore, Singapore DUKE-NUS Medical School, National University of Singapore, Singapore Metabolic Medicine Research Program, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore rinkoo_dalan@ttsh.com.sg.

No MeSH data available.


Related in: MedlinePlus

Box plot of 25(OH)D concentrations (ng/mL) in the vitamin D and placebo group over time.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2 - License 3
getmorefigures.php?uid=PMC4834510&req=5

fig2-1479164115621667: Box plot of 25(OH)D concentrations (ng/mL) in the vitamin D and placebo group over time.

Mentions: In the intervention group, the mean 25(OH)D at baseline was 17.3 ± 5.2 ng/mL, mean adjusted calcium was 2.41 ± 0.10 mmol/L and iPTH was 4.6 ± 1.9 mmol/L. At the 8-week visit, the mean 25(OH)D was 31.3 ± 9.0 ng/mL (change of 14.0 ng/mL; p < 0.0001). No patient developed hypercalcaemia. At 8 weeks, 16 out of 33 [49%; 95% confidence interval (CI): 33%–65%] patients achieved 25(OH)D > 30 ng/mL (75 nmol/L) and had a dose reduction to half their initial dose at the interim visit (Figure 1). At the final 16-week visit, the mean 25(OH)D was 31.6 ± 9.5 ng/mL (change of 14.3 ng/mL; p < 0.0001), mean adjusted calcium was 2.41 ± 0.10 mmol/L and iPTH was 4.5 ± 2.1 mmol/L (Figure 2). At 16 weeks, 23 out of 33 (70%; 95% CI: 53%–83%) patients achieved 25(OH)D > 30 ng/mL (75 nmol/L).


A randomised controlled trial evaluating the impact of targeted vitamin D supplementation on endothelial function in type 2 diabetes mellitus: The DIMENSION trial.

Dalan R, Liew H, Assam PN, Chan ES, Siddiqui FJ, Tan AW, Chew DE, Boehm BO, Leow MK - Diab Vasc Dis Res (2016)

Box plot of 25(OH)D concentrations (ng/mL) in the vitamin D and placebo group over time.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2 - License 3
Show All Figures
getmorefigures.php?uid=PMC4834510&req=5

fig2-1479164115621667: Box plot of 25(OH)D concentrations (ng/mL) in the vitamin D and placebo group over time.
Mentions: In the intervention group, the mean 25(OH)D at baseline was 17.3 ± 5.2 ng/mL, mean adjusted calcium was 2.41 ± 0.10 mmol/L and iPTH was 4.6 ± 1.9 mmol/L. At the 8-week visit, the mean 25(OH)D was 31.3 ± 9.0 ng/mL (change of 14.0 ng/mL; p < 0.0001). No patient developed hypercalcaemia. At 8 weeks, 16 out of 33 [49%; 95% confidence interval (CI): 33%–65%] patients achieved 25(OH)D > 30 ng/mL (75 nmol/L) and had a dose reduction to half their initial dose at the interim visit (Figure 1). At the final 16-week visit, the mean 25(OH)D was 31.6 ± 9.5 ng/mL (change of 14.3 ng/mL; p < 0.0001), mean adjusted calcium was 2.41 ± 0.10 mmol/L and iPTH was 4.5 ± 2.1 mmol/L (Figure 2). At 16 weeks, 23 out of 33 (70%; 95% CI: 53%–83%) patients achieved 25(OH)D > 30 ng/mL (75 nmol/L).

Bottom Line: We compared the change from baseline parameters in the two groups using Student's t-test or Kruskal-Wallis test.The median reactive hyperaemia index in the vitamin D group increased from 0.65 (interquartile range: 0.42) to 0.73 (interquartile range: 0.36), whereas it decreased from 0.73 (interquartile range: 0.65) to 0.65 (interquartile range: 0.38) (p = 0.02) in the placebo group.After adjustment for baseline variables, the change was not statistically significant for reactive hyperaemia index (p = 0.07) and for other vascular biomarkers (p > 0.05).

View Article: PubMed Central - PubMed

Affiliation: Department of Endocrinology, Tan Tock Seng Hospital, Singapore Yong Loo Lin School of Medicine, National University of Singapore, Singapore DUKE-NUS Medical School, National University of Singapore, Singapore Metabolic Medicine Research Program, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore rinkoo_dalan@ttsh.com.sg.

No MeSH data available.


Related in: MedlinePlus